Literature DB >> 23934614

Human intestinal microbiota and type 1 diabetes.

Outi Vaarala1.   

Abstract

The role of intestinal microbiota in immune-mediated diseases, such as type 1 diabetes, has deservedly received a lot of attention. Evidently, changes in the intestinal microbiota are associated with type 1 diabetes as demonstrated by recent studies. Children with beta-cell autoimmunity have shown low abundance of butyrate-producing bacteria and increase in the abundance of members of the Bacteroidetes phylum in fecal microbiota. These alterations could explain increased gut permeability, subclinical small intestinal inflammation, and dysregulation of oral tolerance in type 1 diabetes. However, these studies do not provide evidence of the causative role of the gut microbiota in the development of beta-cell autoimmunity, yet. In animal models, the composition of gut microbiota modulates the function of both innate and adaptive immunity, and intestinal bacteria are regulators of autoimmune diabetes. Thus, prevention of type 1 diabetes could, in the future, be based on the interventions targeted to the gut microbiota.

Entities:  

Mesh:

Year:  2013        PMID: 23934614     DOI: 10.1007/s11892-013-0409-5

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  39 in total

1.  Bacteriotherapy: the time has come.

Authors:  P Huovinen
Journal:  BMJ       Date:  2001-08-18

Review 2.  The role of butyrate in human colonic epithelial cells: an energy source or inducer of differentiation and apoptosis?

Authors:  A Hague; A J Butt; C Paraskeva
Journal:  Proc Nutr Soc       Date:  1996-11       Impact factor: 6.297

3.  Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota.

Authors:  June L Round; Sarkis K Mazmanian
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

4.  Butyrate and type 1 diabetes mellitus: can we fix the intestinal leak?

Authors:  Nan Li; Marguerite Hatch; Clive H Wasserfall; Martha Douglas-Escobar; Mark A Atkinson; Desmond A Schatz; Josef Neu
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-10       Impact factor: 2.839

5.  Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity.

Authors:  Janet G M Markle; Daniel N Frank; Steven Mortin-Toth; Charles E Robertson; Leah M Feazel; Ulrike Rolle-Kampczyk; Martin von Bergen; Kathy D McCoy; Andrew J Macpherson; Jayne S Danska
Journal:  Science       Date:  2013-01-17       Impact factor: 47.728

6.  Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats.

Authors:  Ricardo Valladares; Dhyana Sankar; Nan Li; Emily Williams; Kin-Kwan Lai; Asmaa Sayed Abdelgeliel; Claudio F Gonzalez; Clive H Wasserfall; Joseph Larkin; Desmond Schatz; Mark A Atkinson; Eric W Triplett; Josef Neu; Graciela L Lorca
Journal:  PLoS One       Date:  2010-05-06       Impact factor: 3.240

7.  Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers.

Authors:  Luying Peng; Zhong-Rong Li; Robert S Green; Ian R Holzman; Jing Lin
Journal:  J Nutr       Date:  2009-07-22       Impact factor: 4.798

8.  In vitro-deranged intestinal immune response to gliadin in type 1 diabetes.

Authors:  Renata Auricchio; Francesco Paparo; Maria Maglio; Adriana Franzese; Francesca Lombardi; Giuliana Valerio; Gerardo Nardone; Selvaggia Percopo; Luigi Greco; Riccardo Troncone
Journal:  Diabetes       Date:  2004-07       Impact factor: 9.461

9.  Structure, function and diversity of the healthy human microbiome.

Authors: 
Journal:  Nature       Date:  2012-06-13       Impact factor: 49.962

10.  Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes.

Authors:  Christopher T Brown; Austin G Davis-Richardson; Adriana Giongo; Kelsey A Gano; David B Crabb; Nabanita Mukherjee; George Casella; Jennifer C Drew; Jorma Ilonen; Mikael Knip; Heikki Hyöty; Riitta Veijola; Tuula Simell; Olli Simell; Josef Neu; Clive H Wasserfall; Desmond Schatz; Mark A Atkinson; Eric W Triplett
Journal:  PLoS One       Date:  2011-10-17       Impact factor: 3.240

View more
  35 in total

1.  Gut microbiome compositional and functional differences between tumor and non-tumor adjacent tissues from cohorts from the US and Spain.

Authors:  Imane Allali; Susana Delgado; Pablo Isidro Marron; Aurora Astudillo; Jen Jen Yeh; Hassan Ghazal; Saaïd Amzazi; Temitope Keku; M Andrea Azcarate-Peril
Journal:  Gut Microbes       Date:  2015

Review 2.  Human microbiota, blood group antigens, and disease.

Authors:  D Rose Ewald; Susan C J Sumner
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2018-01-09

Review 3.  Molecular mechanisms in autoimmune type 1 diabetes: a critical review.

Authors:  Zhiguo Xie; Christopher Chang; Zhiguang Zhou
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

Review 4.  Mechanistic links between gut microbial community dynamics, microbial functions and metabolic health.

Authors:  Connie W Y Ha; Yan Y Lam; Andrew J Holmes
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

Review 5.  The dormant blood microbiome in chronic, inflammatory diseases.

Authors:  Marnie Potgieter; Janette Bester; Douglas B Kell; Etheresia Pretorius
Journal:  FEMS Microbiol Rev       Date:  2015-05-03       Impact factor: 16.408

Review 6.  Fecal microbial therapy: promises and pitfalls.

Authors:  Daniel Merenstein; Najwa El-Nachef; Susan V Lynch
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-08       Impact factor: 2.839

Review 7.  Diabetes-related dysfunction of the small intestine and the colon: focus on motility.

Authors:  Viktor József Horváth; Zsuzsanna Putz; Ferenc Izbéki; Anna Erzsébet Körei; László Gerő; Csaba Lengyel; Péter Kempler; Tamás Várkonyi
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

8.  Interleukin-15 promotes intestinal dysbiosis with butyrate deficiency associated with increased susceptibility to colitis.

Authors:  Marlies Meisel; Toufic Mayassi; Hannah Fehlner-Peach; Jason C Koval; Sarah L O'Brien; Reinhard Hinterleitner; Kathryn Lesko; Sangman Kim; Romain Bouziat; Li Chen; Christopher R Weber; Sarkis K Mazmanian; Bana Jabri; Dionysios A Antonopoulos
Journal:  ISME J       Date:  2016-09-20       Impact factor: 10.302

Review 9.  Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics.

Authors:  Momir Mikov; Maja Đanić; Nebojša Pavlović; Bojan Stanimirov; Svetlana Goločorbin-Kon; Karmen Stankov; Hani Al-Salami
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

Review 10.  Biological underpinnings of psychogenic nonepileptic seizures: directions for future research.

Authors:  Ali A Asadi-Pooya
Journal:  Neurol Sci       Date:  2016-03-08       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.